載入中
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
前收盤價
US$2.00
+US$0.01 · +0.50%
盤中時間採用ET。市場資料可能有所延遲。
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$2.00
52週區間
目前US$2.00
盤中時間採用ET。市場資料可能有所延遲。
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$2.00
52週區間
目前US$2.00
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3090.9萬 USD | 2260.2萬 USD | 3415.5萬 USD | 1922.8萬 USD | 131.9萬 USD |
| 銷貨成本 | 333.2萬 USD | — | — | — | — |
| 毛利 | 2757.7萬 USD | 2260.2萬 USD | 3415.5萬 USD | 1922.8萬 USD | 131.9萬 USD |
| 研究與開發 | 8546.6萬 USD | 9452.8萬 USD | 1.1億 USD | 1.06億 USD | 8032.5萬 USD |
| 銷售、一般及管理費用 | 2755萬 USD | 2835.9萬 USD | 3237.2萬 USD | 3074.7萬 USD | 2172.8萬 USD |
| 營業費用 | 1.1億 USD | 1.25億 USD | 1.42億 USD | 1.36億 USD | 1.02億 USD |
| 利息收入 | 874.5萬 USD | 1190萬 USD | 1087.5萬 USD | 567.5萬 USD | 5.9萬 USD |
| 利息支出 | — | — | — | — | 190.6萬 USD |
| 折舊和攤銷 | 333.2萬 USD | 312萬 USD | 345.1萬 USD | 332.1萬 USD | 322.7萬 USD |
| 營業利益 | −8210.7萬 USD | −1.03億 USD | −1.08億 USD | −1.17億 USD | −1.01億 USD |
| 淨利 | −7428.3萬 USD | −8662萬 USD | −9842.6萬 USD | −1.09億 USD | −1.01億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.25
上漲空間 112.50%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI642.12萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF245.85萬0.00%954億 USD0.05%US$235+0.80%
iShares Russell 2000 ETFIWM182.32萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Russell 2000 ETFVTWO120.15萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO67.9萬0.00%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB48.43萬0.00%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 Growth ETFVTWG22.85萬0.01%17億 USD0.06%US$260.49+0.91%
iShares Micro-Cap ETFIWC22.72萬0.02%13.17億 USD0.60%US$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 Growth ETFVTWGiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
